Collection and Storage of Leukopak Biospecimens from Healthy Adults Aged 18 to 89 Supporting Approved Biomedical Research on Rare Diseases

What this Trial Is About

Researchers are collecting and preserving leukopak biospecimens along with detailed medical data from up to 20,000 participants. This large, multi-center observational study aims to support biomedical research projects focused on discovering and developing new treatments, diagnostics, and preventative methods for complex and specific conditions. The collected biospecimens are not intended for transfusion but for research purposes. Participants may have up to two visits a screening visit and an apheresis visit where blood components are collected. The biospecimens gathered through apheresis may be processed, stored frozen, or delivered unfrozen to approved researchers. All samples are anonymized before distribution. The study uses electronic or paper consent forms administered by study staff, and health data is collected by self-report and medical records. During participation, health questionnaires, physical exams, and laboratory tests including blood counts and viral screenings are performed to ensure suitability. Venous access is checked for successful collection. Researchers will measure outcomes related to leukopak collection from September 2022 to September 2024. Participant involvement includes vital sign checks, hemoglobin measurements, and ongoing safety assessments. The study continues until December 2026.

A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives